Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers compared regimens prescribed to pregnant women in their second trimester.
The country’s National Health Service will pay for the drug as part of its goal to end HIV transmission by 2030.
The U.S. PEPFAR program analyzed PrEP scale-up patterns and found that growth was greater among cisgender heterosexuals.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.
Misleading ads about Truvada as PrEP continue to impede HIV prevention.
This is especially the case for people globally who don’t have access to such newer regimens.
Activists want the tech giant to take down similar ads with inaccurate claims about PrEP and HIV prevention.
Despite unanswered questions about PrEP’s safety and efficacy for pregnant women, they shouldn’t be denied Truvada for HIV prevention.
The safety trial will enroll pregnant women in several sub-Saharan African nations.
Who owns the rights to PrEP? The U.S. government or the pharma giant?
They would follow the lead of California, which allows pharmacies to dispense a 30-day supply of the HIV prevention pill without a script.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Canadian researchers analyzed the reasons why people declined a nurse’s offer of PrEP.
It’s not just because of PrEP, which isn’t even easily available in England.
Both Truvada and Descovy are highly effective and safe for most people taking PrEP, but the newer option has more cost barriers.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.